Novo Nordisk A/S (NYSE:NVO) Shares Bought by Kolinsky Wealth Management LLC

Kolinsky Wealth Management LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,351 shares of the company’s stock after acquiring an additional 289 shares during the period. Kolinsky Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Tidal Investments LLC grew its holdings in Novo Nordisk A/S by 13.1% during the 1st quarter. Tidal Investments LLC now owns 4,146 shares of the company’s stock worth $532,000 after acquiring an additional 481 shares in the last quarter. Burney Co. acquired a new position in Novo Nordisk A/S during the 1st quarter worth approximately $243,000. Cetera Investment Advisers grew its holdings in Novo Nordisk A/S by 453.3% during the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock worth $34,095,000 after acquiring an additional 217,545 shares in the last quarter. Cetera Advisors LLC lifted its position in shares of Novo Nordisk A/S by 106.8% during the 1st quarter. Cetera Advisors LLC now owns 63,633 shares of the company’s stock worth $8,170,000 after buying an additional 32,862 shares during the last quarter. Finally, Soltis Investment Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $208,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.6 %

NVO stock opened at $106.80 on Friday. The company has a fifty day moving average price of $112.81 and a 200 day moving average price of $128.00. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a market cap of $479.27 billion, a price-to-earnings ratio of 34.56, a price-to-earnings-growth ratio of 1.37 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent analyst reports. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.